Opinion
Video
Lp(a) Ethnicity and Gender Risks
Michael D. Shapiro, DO, and Erin D. Michos, MD, MHS, discuss the disproportionately high Lp(a) levels seen across different demographic groups, and the need for increased screening and treatment to mitigate the risk of cardiovascular disease.
This is a video synopsis/summary of an Insights involving Michael D. Shapiro, DO, and Erin D. Michos, MD, MHS.
Shapiro details findings from the global lipoprotein(a) (Lp[a]) heritage study, highlighting disparities in Lp(a) levels among racial and gender groups. Notably, individuals of African descent exhibited significantly higher Lp(a) levels, suggesting a need for targeted attention in underserved communities to mitigate cardiovascular risks associated with elevated Lp(a). Michos delves into gender differences in Lp(a) levels, noting that women, particularly postmenopausal ones, showed a slight increase in Lp(a) possibly linked to hormonal changes. Despite this, Lp(a) remains largely genetically determined, with only modest fluctuations observed.
Regarding real-world testing, Michos discusses the underutilization of Lp(a) assessment in clinical practice. Analyses of US claims data among high-risk patients with atherosclerotic cardiovascular disease (ASCVD) revealed minimal Lp(a) screening, indicating a lack of awareness among clinicians. She emphasizes the need to raise awareness and broaden testing criteria, aligning with updated recommendations endorsing universal Lp(a) screening once in a lifetime for all individuals, especially those with unexplained ASCVD or suboptimal responses to statin therapy. These insights stress the necessity of widespread Lp(a) awareness and testing in clinical settings to identify and manage cardiovascular risks effectively.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
